Skip to content

Quantitative 3D UltraSound Brain Imaging: Development of New Bedside Biomarkers to Better Predict Neurodevelopmental Outcomes in Preterm Infants

Quantitative 3D UltraSound Brain Imaging: Development of New Bedside Biomarkers to Better Predict Neurodevelopmental Outcomes in Preterm Infants

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07358819
Acronym
QUSBI
Enrollment
360
Registered
2026-01-22
Start date
2026-04-01
Completion date
2031-04-01
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Very Preterm Infants Born < 30 Weeks of Gestation

Keywords

Very preterm infants, White matter lesions, Neurodevelopment, 3D Cranial Ultrasound, Artificial intelligence, Prediction

Brief summary

Prematurity is a leading cause of neurodevelopmental disorders (NDDs) tightly associated with white matter damage, including punctate white matter lesions (PWMLs). Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential neuroprotective strategies and implement early interventions. 3D and quantitative tools at the bedside using ultrasound are expected to better detect and quantify not only PWMLs but also other brain structures with promising prognostic value to predict NDDs at 2 years of age.

Detailed description

Rationale : Prematurity is a leading cause of neurodevelopmental disorders (NDDs). In Europe, 10% of the 50 000 children born very preterm will develop cerebral palsy and 35% will experience persistent cognitive and neuropsychiatric disorders, including autism, requiring long-term health care support. NDDs following preterm birth are tightly associated with white matter damage, including punctate white matter lesions (PWMLs), a promising marker of subsequent NDDs affecting up to 24% of very preterm infants. Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential neuroprotective strategies and implement early interventions. Magnetic Resonance Imaging (MRI) is the gold standard to assess white matter integrity and has revealed an association between thalamus structure, ventricular dilatation, white matter damage, and NDDs at preschool age in infants born very preterm. However, it suffers from limited accessibility, low portability, and high sensitivity to motion artifacts mitigating its value for screening in all preterm infants at risk of NDDs. Conversely, conventional 2D cranial ultrasonography (cUS) is a tool widely used in neonatal intensive care units to prospectively screen brain lesions through the anterior fontanel. However, while suitable to detect severe lesions observed in 4-5% of very premature infants only, it remains less reliable for the comprehensive detection of PWMLs despite recent improvements. Hence, 3D and quantitative tools at the bedside using ultrasound must be developed to automatically detect and quantify not only PWMLs but also other brain structures with promising prognostic value. Main objective: Identifying new early imaging biomarkers to predict NDDs at 2 years of age. Primary endpoint: Correlation between 3D quantification of PWMLs burden collected between day 3±1 and day 21±3, and results of Bayley Scale assessment, 4th edition, French edition (2022) at 2 years of age and the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, which identifies preterm children at risk for developmental delays at 24 months of age. Secondary objectives: * Developing a processing pipeline allowing the reconstruction of 3D cUS volume & automatic detection and segmentation algorithms based on deep learning methods. * Validating these models to detect PWMLs, & segment thalami and cerebral ventricular system (CVS). * Correlating thalami and CVS 3D longitudinal volumes in very preterm infants with & without PWMLs Secondary endpoints: * Longitudinal cUS data will allow the generation of standard growth curves for thalami and CVS volumes, stratified by sex and dependent on the concurrent detection of PWMLs. * Correlation between 3D quantification of PWMLs burden collected between day 3±1 and day 21±3, and results of the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire. 3D quantification of PWMLs and other 3D cUS tissue segmentations generated using new algorithms developed in WP3 as predictors of (i) MRI findings at term and (ii) neurodevelopmental outcomes at 2 years of age. Impact : This project will improve the quality of care by extending advanced quantitative brain imaging to all very preterm infants and improving the early diagnosis of brain injury. It is also expected to promote personalized medicine approaches and support translational research in neuroprotection through the development of new biomarkers for brain injury. Socio-economic impacts include cost reduction through early identification of at-risk children and timely interventions to prevent severe NDD. QUSBI will also have a significant impact on family support.

Interventions

RADIATIONCranial ultrasound

Dynamic recording of cranial ultrasound assessment with AI-assisted post-processing for brain segmentation at day 3±1, day 8±2, day 21±3, 36 weeks of postmenstrual age, and term equivalent age using bedside cUS.

RADIATIONBrain MRI

Brain MRI at term equivalent of age for all neonates (considered as standard of care for those born before 28 weeks of gestation)

OTHERPARCA-R questionnaire

Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire at 2 years

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
23 Weeks to 35 Weeks
Healthy volunteers
No

Inclusion criteria

* Very preterm infants delivered (either inborn or outborn) between 23+0 and 29+6 weeks of gestation * Informed written consent of the holders of parental authority.

Exclusion criteria

* Admission for palliative care * Chromosomal aberrations and major malformations evidenced after birth Major malformations * Chromosomal aberrations * No social security coverage

Design outcomes

Primary

MeasureTime frameDescription
Identifying new early imaging biomarkers to predict NDDs at 2 years of age.2 yearsCorrelation between 3D quantification of PWMLs burden, and results of Bayley Scale assessment, at 2 years of age and the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, which identifies preterm children at risk for developmental delays at 24 months of age.

Secondary

MeasureTime frameDescription
Developing a processing pipeline allowing the reconstruction of 3D cUS volume & automatic detection and segmentation algorithms based on deep learning methods.Between day 3±1 and day 21±3Longitudinal cUS data will allow the generation of standard growth curves for thalami and CVS volumes, stratified by sex and dependent on the concurrent detection of PWMLs
Validating these models to detect PWMLs, & segment thalami and cerebral ventricular system (CVS).2 yearsCorrelation between 3D quantification of PWMLs burden collected between between day 3±1 and day 21±3 , day 3±1 and term equivalent age, and results of the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire.
Correlating thalami and CVS 3D longitudinal volumes in very preterm infants with & without PWMLs2 years3D quantification of PWMLs and other 3D cUS tissue segmentations generated using new algorithms developed in WP3 as predictors of (i) MRI findings at term and (ii) neurodevelopmental outcomes at 2 years of age

Countries

France

Contacts

CONTACTOlivier BAUD, MD, PhD
olivier.baud@aphp.fr01 58 41 24 23
CONTACTAdèle BELLINO
adele.bellino@aphp.fr01 71 76 07 57
PRINCIPAL_INVESTIGATOROlivier BAUD, MD, PhD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026